Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company committed to developing and commercializing pioneering treatments for patients with serious immunological diseases. The company's primary product candidate, atacicept, is a fusion protein designed for subcutaneous injection once weekly. Atacicept blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the stimulation of B cells and plasma cells that produce autoantibodies contributing to autoimmune diseases such as IgA nephropathy (IgAN) and lupus nephritis.
One of the company's significant achievements is the development of atacicept, which has shown promising results in clinical trials. The Phase 2b ORIGIN clinical trial demonstrated atacicept's potential to modify disease progression in IgAN patients, with data showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, along with stable eGFR over 72 weeks. The ongoing pivotal Phase 3 ORIGIN 3 trial aims to further evaluate atacicept's efficacy and safety in a larger cohort of IgAN patients.
Additionally, Vera is advancing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, which are particularly problematic in kidney transplant patients. Vera retains global developmental and commercial rights to both atacicept and MAU868, positioning the company well in the biopharmaceutical market.
Financially, Vera reported a net loss of $28.4 million for the quarter ended March 31, 2024, with sufficient cash reserves to fund operations through the potential approval and U.S. launch of atacicept. The company has also announced various strategic partnerships and funding rounds to support its ambitious research and development goals.
Recently, Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept in IgAN, indicating the drug's potential to substantially improve kidney function compared to existing therapies. This designation expedites the development and review process, bringing hope to patients suffering from this debilitating disease.
For more information about Vera Therapeutics and its clinical trials, please visit the company's website at www.veratx.com.
Vera Therapeutics, Inc. announced positive interim data from its Phase 2b ORIGIN clinical trial of atacicept in IgA Nephropathy (IgAN), revealing a 41% mean reduction in proteinuria for the 150mg dose group at 24 weeks. The company plans to start a Phase 3 clinical trial in Q2 2023 and expects to release 36-week data from ORIGIN then. Vera reported a net loss of $89.1 million for 2022, increasing from $32.6 million in the previous year. Despite this, it has a strong balance sheet with approximately $188 million from recent follow-on offerings, supporting operations through early 2026.
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston from March 6 – 8, 2023. The chat is scheduled for March 6 at 2:10 PM ET and will be available via webcast. Additionally, the management team will hold one-on-one investor meetings at the event. Vera focuses on developing transformative treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting conditions like IgA nephropathy and lupus nephritis. A replay of the event will be accessible for 90 days on their website.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
What is Vera Therapeutics?
What is atacicept?
What is the ORIGIN clinical trial?
What is IgA nephropathy (IgAN)?
What is MAU868?
What recent achievements has Vera Therapeutics reported?
How is atacicept administered?
What are the financial highlights of Vera Therapeutics?
Who are Vera’s strategic partners?
Where can I find more information about Vera Therapeutics?
